How does the duration of Femoston use affect the breast cancer risk associated with combined hormone replacement therapy?

With Femoston, combined HRT-associated breast cancer risk increases with duration, becoming apparent after about 3 (1–4) years; after stopping, excess risk decreases over time, with return to baseline depending on prior treatment duration, and may persist for 10 years or more after use exceeding 5 years.